Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio. Show more
Location: 6555 Carnegie Avenue, Cleveland, OH, 44103, United States | Website: https://www.abeonatherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
291.3M
52 Wk Range
$3.93 - $7.54
Previous Close
$5.68
Open
$5.67
Volume
273,007
Day Range
$5.62 - $5.82
Enterprise Value
89.82M
Cash
225.5M
Avg Qtr Burn
-16.49M
Insider Ownership
5.78%
Institutional Own.
73.63%
Qtr Updated
06/30/25
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
ZEVASKYN™ (prademagene zamikeracel) Details Recessive dystrophic epidermolysis bullosa | Approved Quarterly sales | |
ABO-102 (AAV-based Gene Therapy) Details Mucopolysaccharidosis type IIIA, Rare genetic disease, Rare diseases, Genetic disorder, Mucopolysaccharidoses | Phase 1/2 Update | |
ABO-101 (AAV-based Gene Therapy) Details Rare diseases, Rare genetic disease, Genetic disorder, Mucopolysaccharidoses, Mucopolysaccharidosis type IIIB | Failed Discontinued |